Donepezil 5 mg

DRUG3 trials

Sponsors

Eisai Co., Ltd., Wake Forest University Health Sciences, Centre Hospitalier St Anne

Conditions

Anorexia Nervosa Restricting TypeCognitive DysfunctionDementia With Lewy Bodies (DLB)Memory Impairment

Phase 2

Acetylcholinesterase Inhibitor in Anorexia Nervosa: Multicenter, Double-Blind, Placebo-Controlled Trial

Not yet recruitingNCT06687993

Centre Hospitalier St AnneAnorexia Nervosa Restricting Type

Start: 2024-11-30End: 2030-05-31Target: 147Updated: 2024-11-14

Phase 3

A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase

CompletedNCT01278407

Eisai Co., Ltd.Dementia With Lewy Bodies (DLB)

Start: 2011-02-28End: 2013-04-30Updated: 2023-06-29

Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil

CompletedNCT02822573

Wake Forest University Health SciencesCognitive Dysfunction, Memory Impairment

Start: 2017-05-30End: 2022-07-29Updated: 2023-09-13

Related Papers

Phase 3 randomized placebo-controlled trial of donepezil for late cancer-related cognitive impairment in breast cancer survivors exposed to chemotherapy from the Wake Forest NCORP Research Base REMEMBER trial (WF97116).

Journal of Clinical Oncology2023-06-016 citations

Phase 3 randomized placebo-controlled trial of donepezil for cancer-related cognitive impairment among breast cancer survivors: Results on patient-reported cognitive function from the wake forest nCI community oncology research program (NCORP) research base REMEMBER trial (WF97116).

Journal of Clinical Oncology2023-06-011 citations

Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial.

2015-02-0366 citations

Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial.

2015-02-0331 citations